Compile Data Set for Download or QSAR
Report error Found 45 Enz. Inhib. hit(s) with Target = 'Receptor-type tyrosine-protein kinase FLT3 [N841I]'
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataKd:  0.0510nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621169(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)...)
Affinity DataKd:  0.0990nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621126(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)...)
Affinity DataKd:  0.150nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621125((R)-N-(6-(6- (difluoromethyl)imidazo[1,2- a]pyridi...)
Affinity DataKd:  0.180nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621098(6-(6-(difluorometh- oxy)imidazo[1,2-a]- pyridin-3-...)
Affinity DataKd:  0.210nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621116(2-(3-(6-(((3S,4S)-4- fluoropyrrolidin-3- yl)amino)...)
Affinity DataKd:  0.220nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621117(2-(3-(6-(((3S,4S)-4- fluoropiperidin-3- yl)amino)p...)
Affinity DataKd:  0.240nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataKd:  0.240nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataKd:  0.330nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621165(Exemplary Synthetic Procedure #38 | US20230303563...)
Affinity DataKd:  0.360nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM185149(Crenolanib | 1-[2-[5-[(3-methyloxetan-3-yl)methoxy...)
Affinity DataKd:  0.390nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621166(N-((3S,4S)-4-fluoro- pyrrolidin-3-yl)-6-(6-(1- met...)
Affinity DataKd:  0.470nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621168(6-(6-(1-cyclopropyl-1H- pyrazol-4-yl)imidazo- [1,2...)
Affinity DataKd:  0.5nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621080(N-(6-(6-(1-methyl- cyclopropyl)imidazo- [1,2-a]pyr...)
Affinity DataKd:  0.600nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.740nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621167(1-(4-(3-(6-(((3S,4S)-4- fluoropyrrolidin-3-yl)- am...)
Affinity DataKd:  0.760nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621130(N-(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-...)
Affinity DataKd:  0.860nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621161(N-((3S,4S)-4- fluoropyrrolidin-3-yl)-6-(7- isoprop...)
Affinity DataKd:  0.910nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538658(NCGC 00249373 | US11254667, Compound I-17 | US1154...)
Affinity DataKd:  1.20nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataKd:  1.20nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(CHEMBL576982 | N-(5-tert-Butyl-isoxazol-3-yl)-N'-{...)
Affinity DataKd:  1.5nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/26/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM31096(CHEMBL290084 | Staurosporine | cid_451705 | US2024...)
Affinity DataKd:  2.10nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM31085(cid_11409972 | 1-[4-[(4-ethylpiperazin-1-yl)methyl...)
Affinity DataKd:  2.30nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM4814(SUNITINIB MALATE | CHEMBL535 | N-[2-(diethylamino)...)
Affinity DataKd:  2.40nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM21079(1-[4-(3-azanyl-1H-indazol-4-yl)phenyl]-3-(2-fluora...)
Affinity DataKd:  2.60nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM13534(VX680 | N-[4-[[4-(4-methylpiperazino)-6-[(5-methyl...)
Affinity DataKd:  4.30nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM25118(4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-...)
Affinity DataKd:  4.80nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM31095(5-[(Z)-(5-fluoranyl-2-oxidanylidene-1H-indol-3-yli...)
Affinity DataKd:  5.40nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM31094(PKC-412 | cid_24202429)
Affinity DataKd:  6nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621136(3,5-difluoro-N-((3S,4S)-4- fluoropyrrolidin-3-yl)-...)
Affinity DataKd:  8.10nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM16673(Xarelto | BAY439006 | CHEMBL1336 | BAY 43-9006 | 4...)
Affinity DataKd:  11nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM247371(US9447092, 1)
Affinity DataKd:  16nMAssay Description:The kinase selectivity was assessed by profiling Example 1 in a 442-kinase panel (386 non-mutant kinases) at a concentration of 1 μM using the K...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2017
Entry Details
US Patent

TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM13535(N-(4-isopropoxyphenyl)-4-[6-methoxy-7-(3-piperidin...)
Affinity DataKd:  29nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM26300(cid_16007391 | 2-{3-[(7-{3-[ethyl(2-hydroxyethyl)a...)
Affinity DataKd:  43nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM5446(Erlotinib | OSI-774 | N-(3-ethynylphenyl)-6,7-bis(...)
Affinity DataKd:  500nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM17055((9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydr...)
Affinity DataKd:  980nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM24773(N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyr...)
Affinity DataKd:  1.10E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  1.20E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM6866(1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogue 3b ...)
Affinity DataKd:  1.40E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM26474(GW-786034 | JMC514632 Compound 13 | 5-({4-[(2,3-di...)
Affinity DataKd:  1.60E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM31090((E)-N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-etho...)
Affinity DataKd:  2.00E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM4779(cid_156414 | PD0183805 | CHEMBL545315 | CHEMBL3196...)
Affinity DataKd:  2.40E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM5447(ZD1839 | N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[...)
Affinity DataKd:  3.00E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM13533(1-[5-tert-butyl-2-(p-tolyl)pyrazol-3-yl]-3-[4-(2-m...)
Affinity DataKd:  5.00E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Human)
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM31099(CHEMBL45741 | Flavopiridol | cid_24867231 | 2-(2-c...)
Affinity DataKd:  6.50E+3nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay